Objective: To investigate the effects of cannabidiol (CBD) on mitochondrial complex and creatine kinase (CK) activity in the rat brain using spectrophotometry. Method: Male adult Wistar rats were given intraperitoneal injections of vehicle or CBD (15, 30, or 60 mg/kg) in an acute (single dose) or chronic (once daily for 14 consecutive days) regimen. The activities of mitochondrial complexes and CK were measured in the hippocampus, striatum, and prefrontal cortex. Results: Both acute and chronic injection of CBD increased the activity of the mitochondrial complexes (I, II, II-III, and IV) and CK in the rat brain. Conclusions: Considering that metabolism impairment is certainly involved in the pathophysiology of mood disorders, the modulation of energy metabolism (e.g., by increased mitochondrial complex and CK activity) by CBD could be an important mechanism implicated in the action of CBD.
Introduction
Although D
9
-tetrahydrocannabinol (D 9 -THC) is commonly accepted as the cannabinoid responsible for the main effects of Cannabis sativa, several reports have demonstrated that other components of the plant can influence its pharmacological activity. 1 One of these components is cannabidiol (CBD), which may constitute up to 40% of cannabis extracts 2 and is devoid of the typical psychological effects of cannabis in humans. 3 Initially considered to be an inactive cannabinoid, CBD has been reported to have a wide range of pharmacological effects, many of which can be of great therapeutic interest. 4 Around the year 2000, most research on the possible therapeutic effects of CBD was focused on its antiepileptic, sedative, anxiolytic, and antipsychotic effects. 5, 6 In recent years, there has been a remarkable increase in CBD-related research, mainly stimulated by the discovery of its anti-inflammatory and neuroprotective effects. These studies have provided evidence of possible therapeutic effects of CBD in several conditions, including Parkinson's disease, Alzheimer's disease, cerebral ischemia, diabetes, rheumatoid arthritis, other inflammatory diseases, nausea, and cancer. 4 Although the mechanisms of action underlying these effects are little known, it has been established that CBD is an antagonist of CB 1 -and CB 2 -receptor agonists, an enhancer of adenosine signaling, has action on the 5-HT1a receptor, and is a potent anti-oxidant. 7 Furthermore, a number of studies have suggested mitochondria as targets for cannabinoids. [8] [9] [10] Mitochondrial abnormalities have been implicated in neuroinflammatory and neurodegenerative conditions and in psychiatric conditions, including schizophrenia, bipolar disorder, and major depression. 11, 12 Mitochondria are the principal source of adenosine triphosphate (ATP), produced through oxidative phosphorylation (OXPHOS). This process is carried out by the respiratory chain complexes I, II, III, and IV, and F1F0-ATP synthase. 13 The central nervous system requires a high energy supply, due to its intense ATP-consuming processes. Thus, abnormal cellular energy metabolism may impair neuronal function and plasticity. 14 Creatine kinase (CK) is an enzyme that catalyzes the reversible transphosphorylation of creatine by ATP, playing a key role in cellular energy buffering and energy transport, particularly in cells with high and fluctuating energy requirements, including neurons. The CK system plays a significant role in the brain; a functional impairment of this system leads to a deterioration in energy metabolism, a characteristic of many mental illnesses. 15 The aim of the present study was to investigate the activities of mitochondrial respiratory chain complexes (I, II, II-III, and IV) and CK in the brain of rats after acute and chronic CBD administration.
Methods

Animals
Forty adult male Wistar rats (250-300 g) were kept on a 12-hour light/dark cycle (lights on at 7:00 a.m.) and constant temperature (22616C). They were housed in plastic cages (five per cage) with water and commercial lab chow ad libitum. All experiments were performed in accordance with the guidelines of the National Institute of Health and with the approval of our Institutional Animal Ethics Committee to minimize suffering and the number of animals sacrificed (protocol no. 51/2009).
Treatment
CBD (THC-Pharm, Frankfurt, Germany) was suspended in 2% polysorbate 80 (Tween 80) dissolved in 0.9% saline solution. The solutions were prepared immediately before use and were protected from light during the experimental session.
Three doses of CBD (15, 30, or 60 mg/kg body weight) in a volume of 1 mL/kg were administered intraperitoneally in two treatments: I) acute, a single injection of CBD was administered (n=5 animals in each group); and II) chronic, CBD was administered once a day for 14 consecutive days (n=5 animals in each group). All control rats for both treatments received injections of 2% polysorbate 80 dissolved in saline (0.9% NaCl) in a volume of 1 mL/kg. The doses of CBD used in this study were based on previous studies. 16, 17 Different animals were used for acute and chronic experiments. Overall, the sample comprised 40 animals.
Brain preparations
Rats were sacrificed by decapitation 2 hours after CBD administration in the acute treatment and 24 hours after the last CBD administration in the chronic treatment. Brains were removed and transferred within 1 min to icecold isolation buffer (0.23 M mannitol, 0.07 M sucrose, 10 mM Tris-HCl, and 1 mM ethylenediaminetetraacetic acid [EDTA], pH 7.4). The prefrontal cortex, hippocampus, striatum, and cerebral cortex (n=5 animals per group) were dissected in ice-cold buffer in a Petri dish.
Activity of mitochondrial respiratory chain enzymes
The prefrontal cortex, hippocampus, striatum, and cerebral cortex were homogenized (1:10, w/v) in SETH buffer (250 mM sucrose, 2 mM EDTA, 10 mM Trizma base, 50 IU/mL heparin, pH 7.4). The homogenates were centrifuged at 800 g for 10 min and the supernatants were used to determine the activities of the mitochondrial respiratory chain enzymes (complexes I, II, II-III, and IV). On the day of the assays, the samples were frozen and thawed thrice in hypotonic assay buffer to fully expose the enzymes to substrates and achieve maximal activities. NADH dehydrogenase (complex I) was evaluated according to the method described by Cassina & Radi 18 by the rate of NADH-dependent ferricyanide reduction at l = 420 nm. The activities of succinate-2,6-dichloroindophenol (DCIP)-oxidoreductase (complex II) and succinate-cytochrome c oxidoreductase (complex II-III) were determined by the method described by Fischer et al. 19 Complex II activity was measured by the decrease in absorbance due to the reduction of 2,6-DCIP at l = 600 nm. Complex II-III activity was measured by cytochrome c reduction from succinate at l = 550 nm. The activity of cytochrome c oxidase (complex IV) was assayed according to the method described by Rustin et al., 20 measured by the decrease in absorbance due to the oxidation of previously reduced cytochrome c at l = 550 nm. The activities of the mitochondrial respiratory chain complexes were calculated as nmol/min/mg protein.
CK activity assay
CK activity was measured in prefrontal, hippocampus, striatum, and cerebral cortex homogenates pre-treated with 0.625 mM lauryl maltoside. The reaction mixture consisted of 60 mM Tris-HCl, pH 7.5, containing 7 mM phosphocreatine, 9 mM MgSO4, and approximately 0.4-1.2 mg protein in a final volume of 100 mL. After 15 min of pre-incubation at 376C, the reaction was started by the addition of 0.3 mmol of adenosine diphosphate (ADP) plus 0.08 mmol of reduced glutathione. The reaction was stopped after 10 min by the addition of 1 mmol of p-(hydroxymercuri)benzoic acid. The creatine formed was estimated according to the colorimetric method of Hughes. 21 The color was developed by the addition of 100 mL 2% a-naphthol and 100 mL 0.05% diacetyl in a final volume of 1 mL and analyzed spectrophotometrically after 20 min at 540 nm. Results were expressed as nmol/min/mg protein.
Statistical analysis
All data are presented as mean 6 standard error (SEM). All data were considered parametric in accordance with the Shapiro-Wilk test for normality (p , 0.05) and the Levene test for homogeneity of variances among groups (p , 0.05). Differences among experimental groups in the open field test and in the assessment of complex I, complex II, complex II-III, complex IV, and CK activity were determined by one-way analysis of variance (ANOVA), followed by Fisher's post-hoc test when ANOVA was significant. P-values , 0.05 were considered statistically significant.
Results
Complex I
A single injection of CBD at a dose of 60 mg/kg increased complex I activity in the prefrontal cortex and in the cerebral cortex, whereas the 30 mg/kg dose increased activity of this enzyme only in the prefrontal cortex ( Figure  1A ). Repeated injections of CBD at doses of 30 and 60 mg/kg increased complex I activity in the prefrontal cortex and in the hippocampus; however, only the 60 mg/kg dose increased complex I activity in the striatum and cerebral cortex ( Figure 1B ).
Complex II
In the rats treated acutely with CBD 60 mg/kg, increased complex II activity was found in the hippocampus, prefrontal cortex, and cerebral cortex; the 30 mg/kg dose was associated with increased complex II activity in the cerebral cortex only (Figure 2A ). The chronic administration of CBD increased complex II activity in the hippocampus, striatum, and cerebral cortex at all doses, and in the prefrontal cortex at the higher doses (30 and 60 mg/kg; Figure 2B ).
Complex II-III
A single injection of CBD at the dose of 60 mg/kg increased complex II-III activity in the prefrontal cortex, hippocampus, and cerebral cortex ( Figure 3A) ; repeated injections of CBD at higher doses increased complex II-III activity in the prefrontal cortex and cerebral cortex ( Figure  3B ).
Complex IV
In rats receiving a single injection of CBD, increased complex IV activity was found in the prefrontal cortex, striatum, and cerebral cortex at the doses of 30 and 60 mg/kg, while increased activity of this enzyme in the hippocampus was observed only when CBD was administered at the highest dose ( Figure 4A ). In rats subjected to repeated injections of CBD, increased Figure 1 Mitochondrial respiratory chain complex I activity in the prefrontal cortex, hippocampus, striatum, and cerebral cortex (n=5 for each group). Bars represent means; error bars represent standard error of means; * p , 0.05 vs. control group, according to ANOVA followed by Fisher's least significant difference (LSD) test. A) Animals subjected to a single injection of cannabidiol (CBD) (15, 30, or 60 mg/ kg) or controls (2% polysorbate 80 in 0.9% saline). Rats were sacrificed by decapitation 2 hours after CBD administration in the acute treatment. B) Animals subjected to repeated injections (once a day for 14 consecutive days) of CBD (15, 30, complex IV activity was observed in the prefrontal and striatum at all doses. In the cerebral cortex, increased activity of this enzyme was found only when CBD was administered at the highest dose ( Figure 4B ).
CK activity
Acute treatment with CBD 60 mg/kg increased CK activity in the hippocampus and cerebral cortex, as compared with vehicle-treated animals. However, CK activity was not altered in the prefrontal cortex or striatum of rats following acute CBD administration ( Figure 5A ).
After chronic treatment with CBD, there was increased CK activity in the hippocampus and striatum at all doses of CBD administered. Finally, in the cerebral cortex, chronic administration of CBD at 30 and 60 mg/kg increased CK activity as compared with the control group. Conversely, chronic CBD administration did not alter CK activity in the prefrontal cortex of rats ( Figure 5B) .
Discussion
The precise mechanisms underlying the therapeutic effects of CBD are still unclear. It has been well established that CBD is an antagonist of CB 1 -and CB 2 -receptor agonists. 22 It is also well known that alterations in brain metabolism are associated with various disorders. Energy impairment has been linked to neuronal death and neurodegeneration. [23] [24] [25] [26] In this work, we evaluated the activities of mitochondrial respiratory chain complexes I, II, II-III, and IV) and CK in the brains of Wistar rats submitted to acute or chronic treatment of CBD. We observed that both the acute and chronic treatment of CBD increased the activity of mitochondrial enzymatic complexes in the brain of rats. A previous study reported that THC can decrease mitochondrial NADH oxidase activity, which is a nonspecific measurement of mitochondrial complex I activity. 8 In rat heart mitochondria, the cannabinoid receptor agonists anandamide, D-9-tetrahydrocannabidiol (THC), Figure 3 Mitochondrial respiratory chain complex II-III activity in the prefrontal cortex, hippocampus, striatum, and cerebral cortex (n=5 for each group). Bars represent means; error bars represent standard error of means; * p , 0.05 vs. control group, according to ANOVA followed by Fisher's least significant difference (LSD) test. A) Animals subjected to a single injection of cannabidiol (CBD) (15, 30, or 60 mg/ kg) or controls (2% polysorbate 80 in 0.9% saline). Rats were sacrificed by decapitation 2 hours after CBD administration in the acute treatment. B) Animals subjected to repeated (once a day for 14 consecutive days) injections of CBD (15, 30, or 60 mg/kg) or controls (2% polysorbate 80 in 0.9% saline). Figure 4 Mitochondrial respiratory chain complex IV activity in the prefrontal cortex, hippocampus, striatum, and cerebral cortex (n=5 for each group). Bars represent means; error bars represent standard error of means; * p , 0.05 vs. control group, according to ANOVA followed by Fisher's least significant difference (LSD) test. A) Animals subjected to a single injection of cannabidiol (CBD) (15, 30, or 60 mg/ kg) or controls (2% polysorbate 80 in 0.9% saline). Rats were sacrificed by decapitation 2 hours after CBD administration in the acute treatment. B) Animals subjected to repeated (once a day for 14 consecutive days) injections of CBD (15, 30, or 60 mg/kg) or controls (2% polysorbate 80 in 0.9% saline).
and HU-210 caused significant decreases in oxygen consumption and mitochondrial membrane potential, decreasing mitochondrial complexes I and II-III and inducing cell death. 10 A recent study has demonstrated that THC and CBD have distinct and often opposing effects on widely distributed neural networks, including the medial temporal lobe, prefrontal cortex, hippocampus, and striatum; these brain regions are rich in cannabinoid receptors and implicated in the pathophysiology of psychosis. 27 This was the first study to evaluate the effects of CBD on the activity of mitochondrial respiratory chain complexes. CBD has low affinity for both known cannabinoid receptors, CB 1 and CB 2 , 22 and appears to have therapeutic potential, with antiepileptic, anxiolytic, antiinflammatory, and even antipsychotic effects. 5, 6 Some studies show that the neuroprotective effects of CBD are associated with reduced intracellular calcium. 3, [28] [29] [30] It is known that mitochondria plays a fundamental role in cellular Ca 2+ homeostasis. 31 Ryan et al. 32 suggested that -sensitive dehydrogenases increases NADH availability and enhances the flow of electrons down the respiratory chain, thus increasing ATP synthesis. 31 Therefore, we suggest that, in the present study, CBD may have increased Ca 2+ accumulation within mitochondria, increasing NADH accessibility and mitochondrial complex activity.
In the present study, chronic CBD treatment increased mitochondrial complex activity in more brain structures and at more CBD doses than acute treatment, depending on the complex evaluated. We suggest that the difference between the experimental protocols can be a cumulative effect of CBD in the chronic treatment regimen. As can be observed, the results presented herein are not consistent across the different steps of the mitochondrial respiratory chain. This might be explained by the fact that the mitochondrial respiratory chain complexes are different enzymes that respond differently to substances and injuries. 33 Complex I is the first step of the respiratory mitochondrial chain, and the most common site for mitochondrial abnormalities. Complex I deficiency is usually found in progressive neurodegenerative disorder. 33 Complex II is the second entry point of reducing equivalents into the respiratory mitochondrial chain via FADH, and it is the only complex that pumps protons across the inner mitochondrial membrane. Complex II inhibition causes an excessive generation of reactive oxygen species and, ultimately, cell death. 34 Complex III represents a confluence point for reducing equivalents from various dehydrogenases; it can catalyze the transfer of electrons from hydroxyquinones. Complex III deficiency is a severe, multisystem disorder, which is characterized by lactic acidosis, hypotonia, hypoglycemia, failure to thrive, encephalopathy, delayed psychomotor development, and early death. 35, 36 Complex IV belongs to the heme-copper oxygen reductase superfamily, whose members catalyze the complete reduction of dioxygen to water and promote proton translocation across the mitochondrial or periplasmic membrane, further contributing to the difference in electrochemical potential. Complex IV deficiency can interrupt the oxidative phosphorylation process, decreasing energy production for the cells to function properly. 33 However, the effects of CBD vary depending on the brain region analyzed. The various regions of the central nervous system may respond differently. 23 Mitochondrial chain complexes were analyzed from different brain regions that, in part, represent different cell types. Furthermore, in this homogeneous network of neurons, there is heterogeneity in terms of physiological and metabolic characteristics. 37 Particularly in the prefrontal cortex and cerebral cortex, CBD always increased the activity of the mitochondrial respiratory chain complexes, in both experimental protocols, mainly at the highest dose. In the hippocampus, CBD administration at the highest tested dose increased the activity of mitochondrial respiratory chain complexes II, II-III, and IV in acute treatment. Chronic CBD administration increased the activity of complexes I (30 and 60 mg/kg) and complex II activity (15, 30 , and 60 mg/kg) in hippocampus. The CB1 receptor is expressed principally in the central nervous system, with the highest concentrations in the prefrontal cortex, anterior cingulate cortex, and hippocampus. 38 CBD has modest antagonistic properties on the CB1 receptor. This effect of CBD on CB1 inhibits the reuptake and hydrolysis of anandamide, and exhibits neuroprotective effects. 39 A previous study demonstrated that exposure to anandamide increases oxidative phosphorylation in brain mitochondria. 40 Perhaps the action of CBD on anandamide increases the activity of mitochondrial complexes in the hippocampus and prefrontal cortex, as observed here. In the striatum, a single administration of CBD at higher doses (30 and 60 mg/ kg) increases the activity of complex IV. After chronic CBD administration, mainly at the higher doses, the activity of complexes I, II, and IV increases in striatum. The CB1 receptor is also densely expressed and functions presynaptically in the lateral striatum, which is directly related to movement. 41, 42 Previous studies have suggested that the striatal actions of CBD may be implicated in its purported antipsychotic effects. 27, 43 In the present work, we also demonstrated that CK activity is increased by acute or chronic administration of CBD in the rat brain. Our results showed that acute CBD administration increased CK activity in the hippocampus and cerebral cortex at the dose of 60 mg/kg. Moreover, acute CBD administration did not alter CK activity in the prefrontal cortex and striatum. On the other hand, chronic administration of CBD increased CK activity in the hippocampus and striatum at all administered doses. In addition, chronic administration of CBD at high doses (30 and 60 mg/kg) increased CK activity in the cerebral cortex. The chronic administration of CBD did not alter CK activity in the prefrontal cortex.
The present study was the first to evaluate the effects of CBD on CK activity. There are no articles in the literature to help us explain the CBD-induced increase in CK observed herein. In a previous study that investigated the global molecular effects of cannabinoids on normal human astrocytes, using genomic and proteomic analyses, treatment with D9-THC was demonstrated to upregulate brain CK protein. 44 The presence of brain CK in Bergmann glial cells and astrocytes is likely related to the energy requirements for ion homeostasis in the brain, as well as for metabolite and neurotransmitter trafficking between glial cells and neurons. CK and its substrates, creatine and phosphocreatine, represent a complex cellular energy buffering and transport system, linking sites of energy production (mitochondria) with sites of energy consumption. 45 Creatine stabilizes mitochondrial CK and reduces opening of the mitochondrial transition pore. 46 In a transgenic animal model of amyotrophic lateral sclerosis, creatine administration protected against increases in oxidative damage in the brain. 47 It has been widely shown that a decrease in CK activity is associated with a neurodegenerative pathway that results in neuronal loss following brain ischemia, 48 neurodegenerative diseases, 49 and other pathological states. 50 Exogenous creatine supplementation has been shown to reduce neuronal cell loss in experimental paradigms of acute and chronic neurological diseases. 51 In line with these findings, preliminary clinical trials have shown beneficial effects of therapeutic creatine supplementation. 52 In conclusion, CBD administration increased complex I, II, II-III, IV, and CK activity in the brains of rats, mainly at the highest dose of CBD (60 mg/kg) and after a prolonged treatment (14 days), suggesting that one of the possible effects of CBD is modulation of brain energy metabolism.
